Loading...
Loading...
BFRI| Name | Value |
|---|---|
| Revenues | 9.0M |
| Cost of Revenue | 2.4M |
| Gross Profit | 6.7M |
| Operating Expense | 11.7M |
| Operating I/L | -5.1M |
| Other Income/Expense | -0.2M |
| Interest Income | 0.0M |
| Pretax | -5.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -5.3M |
Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions in the United States. Its flagship product, Ameluz, is a prescription drug used in combination with the RhodoLED lamp series for photodynamic therapy to treat actinic keratosis. Additionally, the company offers Xepi, a prescription cream for impetigo treatment. Biofrontera generates revenue through the sale of these prescription drugs and medical devices, catering to the needs of patients with dermatological conditions.
